Research and Markets (http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv) has announced the addition of Decision Resources, Inc's new report "DRG Insights: CV Overview (G7)" to their offering.
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. With sales growth of 1.6% year-on-year (YoY), 2011 was a modest period for the Cardiovasculars sector.
This result reflects the fact that the two largest cardiovascular drug classes (the AIIRAs and Statins), with 2011 annual sales of $23.8b and $21.8b, respectively, have reached maturity. Throughout the forecast period, both of these key drug classes will endure sustained losses as a result of aggressive generic erosion that will set in from 2011 onwards (concomitant with the loss of patent protection for Pfizer's Lipitor and Novartis' Diovan).
Key Topics Covered:
Epidemiology & Unmet Needs
Current/Projected Market Share
Drug Sales & Forecasts for each of the following CVD Indications: Acute Coronary Syndrome (UA/NSTEMI/NSTE-ACS)
Arrhythmias (AF Ventricular)
Heart Failure (acute/chronic)
Lipid Disorders (hyperlipidemia/dyslipidemia)
Peripheral Arterial Disease
Pulmonary Arterial Hypertension
For more information visit http://www.researchandmarkets.com/research/vd32l3/drg_insights_cv
Source: Decision Resources, IncBusiness Wire
Last updated on: 08/10/2012